Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Bydureon, Adlyxin, Tanzeum, Eperzan, Orfoglip, and Retara are registered trademarks of their respective owners
Future studies should validate these findings in animal models and further evaluate the long-term effects of C3G therapy on glucose homeostasis and insulin sensitivity, as well as the potential side effects of long-term use of C3G
There was a lack of improvement in power or time to exhaustion during a test at 85% O 2 on a cycle ergometer or in the speed achieved at 4 mmol/lactate in tests of submaximal performance after a marathon race [24]
During phase 1 trials in NASH patients, efocipegtrutide showed a half-life of around 5.9 days, and was capable of reducing body weight by 5.1% when administered weekly at 0.08mg/kg, after 12 weeks [36]